INDEX 06 / ABOUT THIS EDITION

About CJC-1295 Online

An independent editorial project publishing journal-supplement summaries of the peer-reviewed research record on CJC-1295.

What this online edition is

CJC-1295 Online is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. The site is structured as a journal-supplement reading room: mechanism, pharmacokinetics, the DAC-vs-no-DAC distinction, the dosing literature, the reported adverse-effect profile, the 2006 terminated Phase 2 trial, and the current regulatory status of the compound, each documented against citations to the underlying record.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. We do not operate a pharmacy, a compounding facility, or a prescription service. Our work is editorial commentary on publicly available science.

The 'online' in the masthead is an editorial edition marker — 'Online Edition, Vol. 01' — not a commercial signal. The site is a published research index, read from the literature, not a storefront.

Editorial method

Every quantitative claim on this site cites a specific published study. The principal sources are the Teichman 2006 Phase 1 ascending-dose study in healthy adults [3], the Ionescu 2006 continuous-stimulation study [4], the Alba 2006 preclinical GHRH knockout mouse study [8], the Jetté 2005 mechanism paper that first identified CJC-1295 [1], the Coy 1994 D-Ala2 substitution paper [2], the Raun 1998 ipamorelin selectivity paper [12], the ClinicalTrials.gov record for the terminated Phase 2 trial NCT00267527 [9], the aidsmap contemporary report on the 2006 trial halt [5], and the 2024 GH/IGF-1/insulin review [15].

We do not paraphrase claims that are not in the underlying record. Where the published literature is silent — long-term safety, completed Phase 2 efficacy, direct testosterone effects — we say so plainly rather than borrow conclusions from adjacent compounds. The Estilo Suíço Científico register the site is built in is a deliberate match to the editorial standard: cool-white, neo-grotesque, monospace-only-for-data, one accent color, hairline-only rules — the typographic equivalent of a journal supplement, not a marketing brochure.

Regulatory history

CJC-1295 is not approved by the FDA, the EMA, or any other regulator for any therapeutic indication [16]. It is classed as an Investigational New Drug in the United States. Industry development was halted in July 2006 after a fatal adverse event in the ConjuChem Phase 2 lipodystrophy trial (NCT00267527) [5][9]. The FDA removed CJC-1295 and ipamorelin acetate from Section 503A Category 2 (bulk drug substances under evaluation for compounding) effective 27 September 2024, leaving the compound in regulatory limbo [16]. The World Anti-Doping Agency prohibits CJC-1295 under Section S2 in and out of competition [7].

Tesamorelin, a structurally distinct GHRH 1-44 analog with a trans-3-hexenoic acid N-terminal modification, is the only FDA-approved member of the GHRH-analog class [17]. The class has a precedent therapeutic application; CJC-1295 specifically does not share that approval.

Horizontal journal-figure timeline marking the 2006 fatal-adverse-event halt that ended CJC-1295 industry development — Fig. 06 / CJC-1295 regulatory timeline

Schematic timeline of CJC-1295 regulatory history; the cobalt-marked tick is the 2006 fatal-adverse-event halt.

What this site does not claim

No 'doctor' on this masthead, no clinical team, no compounding pharmacy, no telehealth offering, no product, no price. The masthead modifier 'online' is editorial. The site is a journal-supplement reading room — a published reading of a research record, nothing more.

Readers looking for prescription, treatment, or product information should consult their physician. This site is not that resource and does not pretend to be.